Research programme: anticancer therapeutics - Chroma Therapeutics/Infinity Pharmaceuticals
Latest Information Update: 15 May 2008
At a glance
- Originator Chroma Therapeutics; Infinity Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Sep 2006 Discovery Partners International has been acquired and merged into Infinity Pharmaceuticals
- 05 Apr 2005 Preclinical trials in Cancer in USA (unspecified route)